Correlation Between Cell Source and ZyVersa Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cell Source and ZyVersa Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cell Source and ZyVersa Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cell Source and ZyVersa Therapeutics, you can compare the effects of market volatilities on Cell Source and ZyVersa Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cell Source with a short position of ZyVersa Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cell Source and ZyVersa Therapeutics.

Diversification Opportunities for Cell Source and ZyVersa Therapeutics

-0.53

Correlation Coefficient

Cell Source  ZyVersa Therapeutics

Excellent diversification

The 3 months correlation between Cell and ZyVersa is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Cell Source and ZyVersa Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ZyVersa Therapeutics and Cell Source is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cell Source are associated (or correlated) with ZyVersa Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ZyVersa Therapeutics has no effect on the direction of Cell Source i.e., Cell Source and ZyVersa Therapeutics go up and down completely randomly.

Pair Corralation between Cell Source and ZyVersa Therapeutics

Given the investment horizon of 90 days Cell Source is expected to generate 2.53 times more return on investment than ZyVersa Therapeutics. However, Cell Source is 2.53 times more volatile than ZyVersa Therapeutics. It trades about -0.01 of its potential returns per unit of risk. ZyVersa Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  66.00  in Cell Source on October 7, 2024 and sell it today you would lose (25.00) from holding Cell Source or give up 37.88% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Cell Source  vs.  ZyVersa Therapeutics

Cell Source

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cell Source are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak fundamental indicators, Cell Source unveiled solid returns over the last few months and may actually be approaching a breakup point.

ZyVersa Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ZyVersa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Cell Source and ZyVersa Therapeutics

The main advantage of trading using opposite Cell Source and ZyVersa Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cell Source position performs unexpectedly, ZyVersa Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ZyVersa Therapeutics will offset losses from the drop in ZyVersa Therapeutics' long position.

The idea behind Cell Source and ZyVersa Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.